Catalyst
Slingshot members are tracking this event:
Ignyta (RXDX) Presents Phase 1 Data Evaluating Entrectinib in Patients with TRK-, ROS1- or ALK-Positive Solid Tumors
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RXDX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 09, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1, Entrectinib, Trk-, Ros1-, Alk-positive, Solid Tumors
